Efaproxiral-d6

• UNSPSC Description:

  Efaproxiral-d6 is the deuterium labeled Efaproxiral. Efaproxiral (RSR13) is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy[1][2].

• Target Antigen:

  Isotope-Labeled Compounds; Reactive Oxygen Species

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB;Others

• Field of Research:

  Cancer

• Smiles:

  O(C(C(O)=O)(C([2H])([2H])[2H])C([2H])([2H])[2H])C1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1

• Molecular Weight:

  347.44

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94(12):1777-1784.|[3]Abraham DJ, et al. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry. 1992 Sep 29;31(38):9141-9.|[4]Hou H, et al. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res. 2007 Aug;168(2):218-25.|[5]Hou H, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.

• Shipping Conditions:

  Room temperature

• CAS Number:

  1246815-16-6